Valproic acid (VPA) is widely used to treat
epilepsy,
migraine,
chronic headache,
bipolar disorder, and as
adjuvant chemotherapy, but potentially causes idiosyncratic liver injury.
Alpers-Huttenlocher syndrome (AHS), a neurometabolic disorder caused by mutations in
mitochondrial DNA polymerase gamma (POLG), is associated with an increased risk of developing fatal VPA hepatotoxicity. However, the mechanistic link of this clinical mystery remains unknown. Here, fibroblasts from 2 AHS patients were reprogrammed to induced pluripotent stem cells (iPSCs) and then differentiated to hepatocyte-like cells (AHS iPSCs-Hep). Both AHS iPSCs-Hep are more sensitive to VPA-induced mitochondrial-dependent apoptosis than controls, showing more activated
caspase-9 and
cytochrome c release. Strikingly, levels of both soluble and oligomeric
optic atrophy 1, which together keep cristae junctions tight, are reduced in AHS iPSCs-Hep. Furthermore, POLG mutation cells show reduced POLG expression,
mitochondrial DNA (
mtDNA) amount, mitochondrial
adenosine triphosphate production, as well as abnormal mitochondrial ultrastructure after differentiation to hepatocyte-like cells.
Superoxide flashes, spontaneous bursts of
superoxide generation, caused by opening of the
mitochondrial permeability transition pore (mPTP), occur more frequently in AHS iPSCs-Hep. Moreover, the
mPTP inhibitor,
cyclosporine A, rescues VPA-induced apoptotic sensitivity in AHS iPSCs-Hep. This result suggests that targeting
mPTP opening could be an effective method to prevent hepatotoxicity by VPA in AHS patients. In addition,
carnitine or
N-acetylcysteine, which has been used in the treatment of VPA-induced hepatotoxicity, is able to rescue VPA-induced apoptotic sensitivity in AHS iPSCs-Hep.
CONCLUSION: AHS iPSCs-Hep are more sensitive to the VPA-induced mitochondrial-dependent apoptotic pathway, and this effect is mediated by
mPTP opening. Toxicity models in
genetic diseases using iPSCs enable the evaluation of drugs for therapeutic targets.